VitalConnect saw a marked acceleration in adoption of its VistaSolution this past year as COVID-19 pushed telehealth to the forefront of the healthcare market. Caring for patients beyond the confines of the hospital became an urgent need. Healthcare systems looked to leading remote patient monitoring companies who could provide hospital-grade, advanced, technology and could track patients’ symptoms and physiological data in real-time in and outside the hospital.
Expansion into Cardiac Monitoring
November saw the launch of VitalPatch RTM, a cardiac monitoring solution for patients requiring extended Holter monitoring, while also bringing recognition to VitalConnect as healthcare company of the year by The Healthcare insights magazine.
VitalPatch RTM monitors for 21 unique cardiac arrhythmias and captures key vital signs for a more complete view of a patient’s condition. Patient data is collected continuously, in real-time and stored securely in the cloud for physician viewing at any time; a unique capability for an extended Holter monitor.
Along with the launch of VitalPatch RTM, VitalConnect also announced the opening of an independent diagnostic testing facility (IDTF) where patient vitals can be monitored for changes based on physician input and flagged to the physician when it’s necessary.
TELESTAR-TAVR: First-of-its-kind study on how RPM technology can benefit post-TAVR patients
VitalConnect launched a first-of-its-kind trial in 2020, focused on improving outcomes following a transcatheter aortic valve replacement (TAVR) procedure. TELESTAR-TAVR utilizes the latest technology from VitalConnect; VistaSolution LIVE. The primary objective of this prospective trial is to measure the impact of remote patient monitoring (RPM) and telehealth on patient satisfaction, clinical outcomes, and readmission rates for patients.
VitalConnect continues to work with some of the largest pharmaceutical and clinical research organizations in the world. The Vista Solution offers the clinical trial market an efficient, scalable solution to gather critical clinical information. After proven success in initial trials, the Vista Solution will be incorporated in the expansion or addition of new trials.
VistaSolution for COVID management
VitalConnect’s VistaSolution was adopted by several large hospital systems over the past 12 months to help monitor patients inside and outside of the hospital, in order to keep critical bed-space available for sicker patients. The company also received Emergency Use Authorization from the US Food and Drug Administration in May, allowing it to monitor for cardiac arrhythmias which can be a side effect of the COVID-19 virus.
An Exciting Future
As the company enters 2021, VitalConnect has secured additional investor funding and continues to advance its commercial footprint in the extended Holter space while planning expansion and launch into the mobile cardiac telemetry in the first half of 2021. Additionally, the expansion of the Hospital-at-Home market presents a tremendous growth opportunity with VitalConnect’s RPM technology perfectly situated to support this market transformation.